Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Prathap Nagaraja Shastri
Observed names:
Prathap N SHASTRI,
Prathap Shastri
Institution:
Springhouse
Observed institutions:
Centers for Disease Control and Prevention,
Johnson & Johnson (United States),
Mercer University,
Mercer University Health Sciences Center,
Springhouse,
Ambrx (United States),
Janssen Research & Development (United States)
show all 7
ORCID:
0009-0002-8449-8872
Observed ORCID:
0009-0002-8449-8872
OpenAlex ID:
A5031047723
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies
2025
·
Frank R. Brennan
, J. Ryan Polli
, et al.
·
mAbs
·
46
PDF
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
2024
·
Emma Searle
, Christian Recher
, et al.
·
Blood
·
45
Immunogenicity and protection of oral influenza vaccines formulated into microparticles
2012
·
Prathap Nagaraja Shastri
, Min‐Chul Kim
, et al.
·
Journal of Pharmaceutical Sciences
·
37
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
2023
·
Hardik Mody
, Ken Ogasawara
, et al.
·
Clinical Pharmacology & Therapeutics
·
35
PDF
Development and evaluation of polycaprolactone based docetaxel nanoparticle formulation for targeted breast cancer therapy
2020
·
Lakshmi Prasanna Kolluru
, Thripthy Chandran
, et al.
·
Journal of Nanoparticle Research
·
29
Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
2020
·
Prathap Nagaraja Shastri
, Jingjing Zhu
, et al.
·
Molecular Cancer Therapeutics
·
28
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024
·
Lillian K. Skidmore
, David Mills
, et al.
·
Molecular Cancer Therapeutics
·
24
PDF
Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy
2024
·
Jennifer Lynn Ford
, Eleni Karatza
, et al.
·
Clinical Pharmacology & Therapeutics
·
24
Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles
2012
·
Prathap Nagaraja Shastri
, Ruhi V. Ubale
, et al.
·
Drug Development and Industrial Pharmacy
·
24
Increased bioavailability of celecoxib under fed versus fasted conditions is determined by postprandial bile secretion as demonstrated in a dynamic gastrointestinal model
2016
·
Eric Lyng
, Robert Havenaar
, et al.
·
Drug Development and Industrial Pharmacy
·
23
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
2025
·
Hartmut Döhner
, Andre Schuh
, et al.
·
Blood
·
16
PDF
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
2024
·
Prathap Nagaraja Shastri
, Nirav Shah
, et al.
·
Clinical Pharmacology & Therapeutics
·
15
Design of Experiments: A Valuable “Quality by Design” Tool in Formulation Development
2015
·
Lakshmi Kolluru
, Rikhav Gala
, et al.
·
Pan Stanford eBooks
·
9
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
2025
·
Jenny O'Nions
, Andrew Wei
, et al.
·
Blood
·
6
Pulmonary Administration of Microparticulate Antisense Oligonucleotide (ASO) for the Treatment of Lung Inflammation
2018
·
Ruhi V. Ubale
, Prathap Nagaraja Shastri
, et al.
·
AAPS PharmSciTech
·
6
Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer
2023
·
Lillian Skidmore
, David Mills
, et al.
·
Cancer Research
·
5
Immune-potentiation of Pneumococcal Capsular Polysaccharide Antigen using Albumin Microparticles
2018
·
Bernadette D Souza
, Prathap Nagaraja Shastri
, et al.
·
Journal of Pharmacovigilance
·
5
PDF
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
2025
·
Marc Raaijmakers
, Hartmut Döhner
, et al.
·
Blood
·
4
FDA Expedited Drug Development Programs
2016
·
Prathap Nagaraja Shastri
·
Journal of Pharmacovigilance
·
4
PDF
2015 Pharmaceutical Industry Roundup
2016
·
Prathap Nagaraja Shastri
·
Journal of Pharmacovigilance
·
3
Immunogenicity of Microparticulate Influenza Vaccine
2015
·
Prathap Shastri
, Trinh Vo
, et al.
·
Pan Stanford eBooks
·
2
Microparticulate Formulation for a Pneumococcal Capsular Polysaccharide Antigen
2015
·
Bernadette D'Souza
, Prathap Shastri
, et al.
·
Pan Stanford eBooks
·
2
Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations
2026
·
Hartmut Döhner
, Andre C. Schuh
, et al.
·
Transplantation and Cellular Therapy
·
1
Bispecific antibodies that engage pIgR enrich in mucosa in cynomolgus monkeys
2026
·
Kelsie Marks
, Nirav Shah
, et al.
·
mAbs
PDF
No Evidence of Qtc Interval Prolongation With the Menin Inhibitor Bleximenib When Given as Monotherapy or in Combination With Acute Myeloid Leukemia Aml-directed Therapies for Kmt2a or Npm1 Altered Aml
2026
·
Maher ABDUL-HAY
, Sameem ABEDIN
, et al.
·
Hematology Transfusion and Cell Therapy
Show more works
View as search
Works count:
46
Citation count:
393
H-index:
12
I10-index:
12
Year
Topic
Type